FDA approves Takeda's orexin agonist for narcolepsy type 1

The U.S. Food and Drug Administration approved a novel narcolepsy treatment on Wednesday, August 5, 2026, marking the first therapy designed to address the underlying biology of the disorder rather than just its symptoms. The drug, oveporexton, will be marketed by Takeda Pharmaceutical as Orzeyful for adults with narcolepsy type 1.

Narcolepsy type 1 is a chronic neurological disorder caused by the loss of orexin-producing neurons in the brain, leading to insufficient levels of this chemical messenger that regulates wakefulness, sleep, and muscle tone. This deficiency results in symptoms including excessive daytime sleepiness and cataplexy, a sudden loss of muscle tone often triggered by strong emotions. For decades, treatments have focused on managing these individual symptoms with stimulants or other medications.

Orzeyful represents a fundamental shift in approach. As an orexin receptor 2 agonist, the twice-daily oral tablet works by directly activating the same signaling pathway that is deficient in patients, aiming to restore orexin activity. In a statement, Tiffany Farchione, director of the division of psychiatry in the FDA's Center for Drug Evaluation and Research, said...